The value of <sup>68</sup> Gallium-DOTATATE PET/CT in sinonasal neuroendocrine tumor management: A case series.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 33786927.
- Also identified by DOI 10.1002/hed.26695.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<sup>68</sup> Gallium-DOTATATE (<sup>68</sup> Ga-DOTATATE) is a somatostatin analog used as a PET tracer to successfully identify neuroendocrine tumors (NETs). Due to the rarity of sinonasal NETs, there are few recommendations for <sup>68</sup> Ga-DOTATATE imaging in these patients. We discussed the impact of <sup>68</sup> Ga-DOTATATE imaging on the management of six sinonasal NET cases and reviewed existing literature. <sup>68</sup> Ga-DOTATATE PET/CT revealed an unknown primary in one case and identified metastatic disease in a primary sinonasal small cell neuroendocrine carcinoma (SNEC) patient missed on conventional imaging. In two esthesioneuroblastoma (ENB) patients, <sup>68</sup> Ga-DOTATATE detected abnormal radiotracer uptake not present on 18F-FDG PET/CT and identified a patient for treatment with <sup>177</sup> Lu-DOTATATE. This is the one of the first few reports, and the largest series to our knowledge, demonstrating the utility of <sup>68</sup> Ga-DOTATATE imaging for primary sinonasal SNEC and ENB. Further study is required to determine its role in sinonasal NET management.
Medical subject headings
- Gallium
- Neuroendocrine Tumors
- Organometallic Compounds